3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
9
Phase 3
4
Phase 2
4
Phase NA
3
Phase 1/2
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mastocytosis
1
Liver Neoplasms
1
Gastroenteropancreatic Neuroendocrine Tumors
1
GATA2 Deficiency
1
Colorectal Neoplasms
1
Advanced Solid Tumor
1
Interventions
Docetaxel
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Prednisone
5
Androgen Antagonists
5
gallium 68 PSMA-11
4
enzalutamide
3
bicalutamide
3
Triptorelin Pamoate
3
Radiosurgery
3
Leuprolide
3
Goserelin
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
abiraterone
2
Zoledronic Acid
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Mitoxantrone
2
Flutamide
2
Celecoxib
2
Abiraterone Acetate
2
satraplatin
1
relugolix
1
pertuzumab
1
nilutamide
1
maltodextrin
1
luprolide acetate gel depot
1
histrelin
1
genistein combined polysaccharide
1
fluciclovine F-18
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Prostatic Neoplasms
×
Injections
×
Clear all
NCT06282588
2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3
Recruiting
493 enrolled